BACKGROUND: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: We retrospectively analyzed clinical, renal, and salivary scintigraphy data and salivary [68Ga]Ga-PSMA-11 ligand PET scan measures such as metabolic volume and SUVmax values of 27 mCRPC men (mean age 71 ± 7 years) before and 4 weeks after receiving three cycles of PSMA-RLT every 4 weeks. Twenty-two patients additionally obtained renal and salivary scintigraphy prior to each cycle. A one-way ANOVA, post-hoc Scheffé test and Cochran's Q test were applied to assess organ toxicity. RESULTS: In total, 54 PSMA PET scans, 98 kidney, and 98 salivary scintigraphy results were evaluated. There were no significant differences for the ejection fraction, peak time, and residual activity after 5 min for both parotid and submandibular glands prior to each cycle and 4 weeks after the last cycle. Similarly, no significant differences in serum creatinine and renal scintigraphy parameters were observed prior to each cycle and 4 weeks after the last treatment. Despite there being no changes in the metabolic volume of both submandibular glands, SUVmax values dropped significantly (p < 0.05). CONCLUSION: Results evidenced no alterations in renal function and only minimal impairment of salivary function of mCRPC patients who acquired an intense PSMA-RLT regimen every 4 weeks.

Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna 1090 Vienna Austria

Department of Biomedical Imaging and Image Guided Therapy Division of General Radiology Medical University of Vienna 1090 Vienna Austria

Department of Biomedical Imaging and Image Guided Therapy Division of Nuclear Medicine Medical University of Vienna 1090 Vienna Austria

Department of Urology 2nd Faculty of Medicine Charles University 15006 Prague Czech Republic

Department of Urology Medical University of Vienna 1090 Vienna Austria

Department of Urology University of Texas Southwestern Medical Center Dallas TX 75390 USA

Department of Urology Weill Cornell Medical College New York NY 10065 USA

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University 119991 Moscow Russia

Ludwig Boltzmann Institute Applied Diagnostics 1090 Vienna Austria

Zobrazit více v PubMed

Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Sweat S.D., Pacelli A., Murphy G.P., Bostwick D.G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–640. doi: 10.1016/S0090-4295(98)00278-7. PubMed DOI

Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004;91:528–539. doi: 10.1002/jcb.10661. PubMed DOI

O’Keefe D.S., Bacich D.J., Huang S.S., Heston W.D. A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. J. Nucl. Med. 2018;59:1007–1013. doi: 10.2967/jnumed.117.203877. PubMed DOI PMC

Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997;3:81–85. PubMed

Bostwick D.G., Pacelli A., Blute M., Roche P., Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer. 1998;82:2256–2261. doi: 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S. PubMed DOI

Hillier S.M., Maresca K.P., Lu G., Merkin R.D., Marquis J.C., Zimmerman C.N., Eckelman W.C., Joyal J.L., Babich J.W. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J. Nucl. Med. 2013;54:1369–1376. doi: 10.2967/jnumed.112.116624. PubMed DOI

Eder M., Schäfer M., Bauder-Wüst U., Hull W.-E., Wängler C., Mier W., Haberkorn U., Eisenhut M. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjug. Chem. 2012;23:688–697. doi: 10.1021/bc200279b. PubMed DOI

Weineisen M., Schottelius M., Simecek J., Baum R.P., Yildiz A., Beykan S., Kulkarni H.R., Lassmann M., Klette I., Eiber M., et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015;56:1169–1176. PubMed

Mease R.C., Dusich C.L., Foss C.A., Ravert H.T., Dannals R.F., Seidel J., Prideaux A., Fox J.J., Sgouros G., Kozikowski A.P., et al. N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer. Clin. Cancer Res. 2008;14:3036–3043. doi: 10.1158/1078-0432.CCR-07-1517. PubMed DOI PMC

Kratochwil C., Bruchertseifer F., Giesel F.L., Weis M., Verburg F.A., Mottaghy F., Kopka K., Apostolidis C., Haberkorn U., Morgenstern A. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016;57:1941–1944. doi: 10.2967/jnumed.116.178673. PubMed DOI

Rice M., Malhotra S.V., Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front. Oncol. 2019;9:801. doi: 10.3389/fonc.2019.00801. PubMed DOI PMC

Nuhn P., De Bono J.S., Fizazi K., Freedland S.J., Grilli M., Kantoff P.W., Sonpavde G., Sternberg C.N., Yegnasubramanian S., Antonarakis E.S. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur. Urol. 2018;75:88–99. doi: 10.1016/j.eururo.2018.03.028. PubMed DOI

Nguyen-Nielsen M., Borre M. Diagnostic and Therapeutic Strategies for Prostate Cancer. Semin. Nucl. Med. 2016;46:484–490. doi: 10.1053/j.semnuclmed.2016.07.002. PubMed DOI

Hofman M.S., Emmett L., Sandhu S., Iravani A., Joshua A.M., Goh J.C., Pattison D.A., Tan T.H., Kirkwood I.D., Ng S., et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804. doi: 10.1016/S0140-6736(21)00237-3. PubMed DOI

Novartis Announces Positive Result of Phase III Study with Radioligand Therapy 177Lu-PSMA-617 in Patients with Advanced Prostate Cancer. [(accessed on 23 March 2021)]. Available online: https://bit.ly/3ce0zCQ.

Rahbar K., Ahmadzadehfar H., Kratochwil C., Haberkorn U., Schäfers M., Essler M., Baum R.P., Kulkarni H.R., Schmidt M., Drzezga A., et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J. Nucl. Med. 2017;58:85–90. doi: 10.2967/jnumed.116.183194. PubMed DOI

Bräuer A., Grubert L.S., Roll W., Schrader A.J., Schäfers M., Bögemann M., Rahbar K. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:1663–1670. doi: 10.1007/s00259-017-3751-z. PubMed DOI

Kratochwil C., Giesel F.L., Eder M., Afshar-Oromieh A., Benešová M., Mier W., Kopka K., Haberkorn U. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015;42:987–988. doi: 10.1007/s00259-014-2978-1. PubMed DOI

Rahbar K., Boegemann M., Yordanova A., Eveslage M., Schäfers M., Essler M., Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur. J. Nucl. Med. Mol. Imaging. 2017;45:12–19. doi: 10.1007/s00259-017-3848-4. PubMed DOI

O’Keefe D.S., Bacich D.J., Heston W.D. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004;58:200–210. doi: 10.1002/pros.10319. PubMed DOI

Tönnesmann R., Meyer P.T., Eder M., Baranski A.-C. [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography. Pharmaceuticals. 2019;12:18. doi: 10.3390/ph12010018. PubMed DOI PMC

Yordanova A., Becker A., Eppard E., Kürpig S., Fisang C., Feldmann G., Essler M., Ahmadzadehfar H. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:1473–1479. doi: 10.1007/s00259-017-3681-9. PubMed DOI

Delker A., Fendler W.P., Kratochwil C., Brunegraf A., Gosewisch A., Gildehaus F.J., Tritschler S., Stief C.G., Kopka K., Haberkorn U., et al. Dosimetry for 177Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015;43:42–51. doi: 10.1007/s00259-015-3174-7. PubMed DOI

Kabasakal L., Abuqbeitah M., Aygün A., Yeyin N., Ocak M., Demirci E., Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015;42:1976–1983. doi: 10.1007/s00259-015-3125-3. PubMed DOI

Özkan A., Uçar B., Seymen H., Yarar Y.Y., Falay F.O., Demirkol M.O. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results. Clin. Nucl. Med. 2020;45:288–291. doi: 10.1097/RLU.0000000000002942. PubMed DOI

Kratochwil C., Giesel F.L., Stefanova M., Benešová M., Bronzel M., Afshar-Oromieh A., Mier W., Eder M., Kopka K., Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. J. Nucl. Med. 2016;57:1170–1176. doi: 10.2967/jnumed.115.171397. PubMed DOI

Yadav M.P., Ballal S., Sahoo R.K., Dwivedi S.N., Bal C. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Am. J. Roentgenol. 2019;213:275–285. doi: 10.2214/AJR.18.20845. PubMed DOI

Rasul S., Hacker M., Kretschmer-Chott E., Leisser A., Grubmüller B., Kramer G., Shariat S., Wadsak W., Mitterhauser M., Hartenbach M., et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur. J. Nucl. Med. Mol. Imaging. 2019;47:713–720. doi: 10.1007/s00259-019-04584-1. PubMed DOI PMC

Rasul S., Hartenbach M., Wollenweber T., Kretschmer-Chott E., Grubmüller B., Kramer G., Shariat S., Wadsak W., Mitterhauser M., Pichler V., et al. Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020;48:1650–1657. doi: 10.1007/s00259-020-05082-5. PubMed DOI PMC

Ahmadzadehfar H., Rahbar K., Kürpig S., Bögemann M., Claesener M., Eppard E., Gärtner F., Rogenhofer S., Schäfers M., Essler M. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study. EJNMMI Res. 2015;5:114. doi: 10.1186/s13550-015-0114-2. PubMed DOI PMC

Rasul S., Wollenweber T., Zisser L., Kretschmer-Chott E., Grubmüller B., Kramer G., Shariat S., Eidherr H., Mitterhauser M., Vraka C., et al. Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers. 2021;13:2489. doi: 10.3390/cancers13102489. PubMed DOI PMC

Shizukuishi K., Nagaoka S., Kinno Y., Saito M., Takahashi N., Kawamoto M., Abe A., Jin L., Inoue T. Scoring analysis of salivary gland scintigraphy in patients with Sjögren’s syndrome. Ann. Nucl. Med. 2003;17:627–631. doi: 10.1007/BF02984967. PubMed DOI

Vitali C., Bombardieri S., Moutsopoulos H.M., Coll J., Gerli R., Hatron P.Y., Kater L., Konttinen Y.T., Manthorpe R., Meyer O., et al. Assessment of the European classification criteria for Sjögren’s syndrome in a series of clinically defined cases: Results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren’s Syndrome. Ann. Rheum. Dis. 1996;55:116–121. doi: 10.1136/ard.55.2.116. PubMed DOI PMC

Klutmann S., Bohuslavizki K.H., Kröger S., Bleckmann C., Brenner W., Mester J., Clausen M. Quantitative salivary gland scintigraphy. J. Nucl. Med. Technol. 1999;27:20–26. PubMed

Taylor A.T., Brandon D.C., de Palma D., Blaufox M.D., Durand E., Erbas B., Grant S.F., Hilson A.J., Morsing A. SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. Semin. Nucl. Med. 2018;48:377–390. doi: 10.1053/j.semnuclmed.2018.02.010. PubMed DOI PMC

Peters A.M. Graphical analysis of dynamic data: The Patlak-Rutland plot. Nucl. Med. Commun. 1994;15:669–672. doi: 10.1097/00006231-199409000-00001. PubMed DOI

Piepsz A., Kinthaert J., Tondeur M., Ham H.R. The robustness of the Patlak-Rutland slope for the determination of split renal function. Nucl. Med. Commun. 1996;17:817–821. doi: 10.1097/00006231-199609000-00014. PubMed DOI

Gates G.F. Glomerular filtration rate: Estimation from fractional renal accumulation of 99mTc-DTPA (stannous) Am. J. Roentgenol. 1982;138:565–570. doi: 10.2214/ajr.138.3.565. PubMed DOI

Esteves F.P., Halkar R.K., Issa M.M., Grant S., Taylor A. Comparison of camera-based 99mTc-MAG3 and 24-h creatinine clearances for evaluation of kidney function. Am. J. Roentgenol. 2006;187:W316–W319. doi: 10.2214/AJR.05.1025. PubMed DOI

Grubmüller B., Senn D., Kramer G., Baltzer P., D’Andrea D., Grubmüller K.H., Mitterhauser M., Eidherr H., Haug A.R., Wadsak W., et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2019;46:1063–1072. doi: 10.1007/s00259-018-4236-4. PubMed DOI PMC

Van Kalmthout L.W.M., Lam M.G.E.H., De Keizer B., Krijger G.C., Ververs T.F.T., De Roos R., Braat A.J.A.T. Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands. EJNMMI Res. 2018;8:56. doi: 10.1186/s13550-018-0408-2. PubMed DOI PMC

Fendler W.P., Reinhardt S., Ilhan H., Delker A., Böning G., Gildehaus F.J., Stief C., Bartenstein P., Gratzke C., Lehner S., et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2016;8:3581–3590. doi: 10.18632/oncotarget.12240. PubMed DOI PMC

Ahmadzadehfar H., Eppard E., Kürpig S., Fimmers R., Yordanova A., Schlenkhoff C.D., Gartner F., Rogenhofer S., Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–12488. doi: 10.18632/oncotarget.7245. PubMed DOI PMC

Rahbar K., Bode A., Weckesser M., Avramovic N., Claesener M., Stegger L., Bögemann M. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clin. Nucl. Med. 2016;41:522–528. doi: 10.1097/RLU.0000000000001240. PubMed DOI

Scarpa L., Buxbaum S., Kendler D., Fink K., Bektic J., Gruber L., Decristoforo C., Uprimny C., Lukas P., Horninger W., et al. The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: Correlation of SUV(max) values and absorbed dose estimates. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:788–800. doi: 10.1007/s00259-016-3609-9. PubMed DOI

Hofman M.S., Violet J., Hicks R.J., Ferdinandus J., Thang S.P., Akhurst T., Iravani A., Kong G., Kumar A.R., Murphy D.G., et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–833. doi: 10.1016/S1470-2045(18)30198-0. PubMed DOI

Wolf P., Freudenberg N., Bühler P., Alt K., Schultze-Seemann W., Wetterauer U., Elsässer-Beile U. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2009;70:562–569. doi: 10.1002/pros.21090. PubMed DOI

Taïeb D., Foletti J.-M., Bardiès M., Rocchi P., Hicks R.J., Haberkorn U. PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? J. Nucl. Med. 2018;59:747–748. doi: 10.2967/jnumed.118.207993. PubMed DOI

Sathekge M.M., Bruchertseifer F., Vorster M., Morgenstern A., Lawal I.O. Global experience with PSMA-based alpha therapy in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2021;26:1–7. PubMed PMC

Filippi L., Chiaravalloti A., Schillaci O., Bagni O. The potential of PSMA-targeted alpha therapy in the management of prostate cancer. Expert Rev. Anticancer. Ther. 2020;20:823–829. doi: 10.1080/14737140.2020.1814151. PubMed DOI

Rosar F., Kochems N., Bartholomä M., Maus S., Stemler T., Linxweiler J., Khreish F., Ezziddin S. Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers. 2021;13:3095. doi: 10.3390/cancers13123095. PubMed DOI PMC

Gallyamov M., Meyrick D., Barley J., Lenzo N. Renal outcomes of radioligand therapy: Experience of 177lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. Clin. Kidney J. 2019;13:1049–1055. doi: 10.1093/ckj/sfz101. PubMed DOI PMC

Ngoc C.N., Happel C., Davis K., Groener D., Mader N., Mandel P., Tselis N., Gruenwald F., Sabet A. Renal Function after Radioligand Treatment with 177Lu-PSMA-617. J. Nucl. Med. 2020;61((Suppl. 1)):1279.

Yadav M.P., Ballal S., Tripathi M., Damle N.A., Sahoo R.K., Seth A., Tselis N., Gruenwald F., Sabet A. (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: Safety, efficacy, and quality of life assessment. Eur. J. Nucl. Med. Mol. Imaging. 2017;44:81–91. doi: 10.1007/s00259-016-3481-7. PubMed DOI

Rahbar K., Schmidt M., Heinzel A., Eppard E., Bode A., Yordanova A., Claesener M., Ahmadzadehfar H. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J. Nucl. Med. 2016;57:1334–1338. doi: 10.2967/jnumed.116.173757. PubMed DOI